At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 338 enrolled
Drug / intervention
LY3437943 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
In Brief
A Phase 2 clinical trial evaluating LY3437943 and Placebo for Obesity and Overweight. Completed, enrolled 338 participants across 28 sites in 2 countries.
Detailed Summary
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartMay 2021
Primary CompletionMay 2022
Study CompletionNov 2022
TodayJul 2026
First PostedMay 11, 2021
Enrollment StartMay 20, 2021
Primary CompletionMay 16, 2022
Study CompletionNov 22, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.1 years ago
Interventions
LY3437943drug
Administered SC
Placebodrug
Administered SC